Navigation Links
Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
Date:3/7/2012

SAN DIEGO, March  7, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the following two investor conferences in March:

  • 24th Annual Roth Conference in Dana Point on March 14, 2012 at 12:30 p.m. ET/9:30 a.m. PT. Kurt Gustafson, Chief Financial Officer of Halozyme Therapeutics, will provide a corporate overview.
  • Barclays Capital 2012 Global Healthcare Conference in Miami on March 14, 2012 at 4:15 p.m. ET/1:15 p.m. PT. Gregory I. Frost, Ph.D., President and Chief Executive Officer of Halozyme Therapeutics, will provide a corporate overview.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentations will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and recordings will be made available for 90 days following the events. To access the live webcasts, please log on to Halozyme's website approximately fifteen minutes prior to the presentations to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
858-704-8264
aerickson@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
2. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
3. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
4. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
5. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
6. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
7. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
8. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
9. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
10. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
11. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... USA (PRWEB) , ... May 23, 2017 , ... Federal ... as well as an enabler of life-saving medical and other vital technologies — deserves ... . They joined others in the scientific community today in responding to the President’s ...
(Date:5/23/2017)... (PRWEB) , ... May 23, ... ... offer an unlimited source of human cardiovascular cells for research and the ... methods makes it possible to generate large numbers of cardiomyocytes (hPSC-CMs). Due ...
(Date:5/23/2017)... ... May 23, 2017 , ... Energetiq Technology, a world ... facility expansion to accommodate its rapid growth. , The renovations at the company’s ... of the existing areas. The expansion includes, a state-of-the-art engineering facility, and a ...
(Date:5/22/2017)... ... May 22, 2017 , ... Stratevi, a boutique firm ... the East Coast. It has opened an office in downtown Boston at 745 Atlantic ... it increasingly more important to generate evidence on the value they provide, not just ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
Breaking Biology News(10 mins):